Pulmatrix (NASDAQ:PULM) Share Price Passes Below Fifty Day Moving Average of $3.78

Pulmatrix, Inc. (NASDAQ:PULMGet Rating) crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.78 and traded as low as $3.70. Pulmatrix shares last traded at $3.74, with a volume of 21,064 shares.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Pulmatrix in a research note on Tuesday. They set a “hold” rating for the company.

Pulmatrix Stock Down 1.6 %

The firm’s 50 day simple moving average is $3.78 and its two-hundred day simple moving average is $4.02.

Pulmatrix (NASDAQ:PULMGet Rating) last posted its quarterly earnings results on Thursday, November 10th. The biotechnology company reported ($1.45) earnings per share for the quarter, beating the consensus estimate of ($1.51) by $0.06. Pulmatrix had a negative net margin of 387.03% and a negative return on equity of 46.03%. The firm had revenue of $1.87 million during the quarter, compared to the consensus estimate of $1.16 million. On average, equities research analysts predict that Pulmatrix, Inc. will post -6.04 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pulmatrix stock. Citadel Advisors LLC acquired a new stake in shares of Pulmatrix, Inc. (NASDAQ:PULMGet Rating) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 30,628 shares of the biotechnology company’s stock, valued at approximately $141,000. Citadel Advisors LLC owned about 0.90% of Pulmatrix at the end of the most recent reporting period. 15.69% of the stock is currently owned by institutional investors and hedge funds.

Pulmatrix Company Profile

(Get Rating)

Pulmatrix, Inc is a clinical stage biotechnology company engaged in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Read More

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.